2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Erratum (v17,p314) All Versions of this Article: ASN.2005020138v1 16/10/3038    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmieder, R. E. Articles by Delles, C. Search for Related Content PubMed PubMed Citation Articles by Schmieder, R. E. Articles by Delles, C.

Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study

Department of Medicine IV, University of Erlangen-Nürnberg, Erlangen, Germany

Address correspondence to: Prof. Roland E. Schmieder, Universitätsklinikum Erlangen, Medizinische Klinik IV, Krankenhausstrasse 12, Erlangen 91054, Germany. Phone: +49-9131-853-6245; Fax: +49-9131-853-9209; E-mail: roland.schmieder{at}rzmail.uni-erlangen.de

Received for publication February 4, 2005. Accepted for publication July 14, 2005.

Proteinuria indicates future renal and cardiovascular morbidity, and, conversely, its reduction is associated with improved outcome. In a randomized, double-blind trial with parallel group design, the antiproteinuric effect of candesartan at high doses was analyzed. Patients with normal or mildly impaired renal function, protein excretion rate of 1 to 10 g/d, and treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for 3 mo were eligible. After a 4-wk treatment with 16 mg/d candesartan, patients (n = 32) were allocated to double-blind therapy with either 32 or 64 mg/d candesartan for 12 wk (including 4 wk of uptitration), followed again by 4 wk of candesartan 16 mg/d. Proteinuria at study entry was similar in both groups (geometric mean [95% confidence interval (CI)]; 32 mg/d candesartan 2.14 g/d [95% CI, 1.45 to 3.17]; 64 mg/d candesartan 2.54 g/d [95% CI, 1.91 to 3.40]; NS). After the double-blind treatment phase, proteinuria was reduced to 1.42 g/d (0.85 to 2.37) in the 64-mg/d group (P = 0.017), without any change in the 32-mg/d group (2.02 g/d [95% CI, 1.26 to 3.26]). The change in proteinuria differed between the two groups in absolute (P = 0.025) and relative terms (–29 ± 50 versus –0 ± 26%; P = 0.012). After downtitration to 16 mg/d candesartan, proteinuria increased again to 2.38 g/d (1.57 to 3.62) in the 64-mg/d group (P = 0.001) but remained unchanged in the 32-mg/d group (2.04 g/d [95% CI, 1.17 to 3.57]; NS). No change in BP was noticed in response to the different doses of candesartan. These data indicate an additive antiproteinuric effect of ultrahigh dose of the angiotensin receptor blocker candesartan compared with standard dose.

This article has been cited by other articles:

				S. HIRSCH An update on proteinuric chronic kidney disease: The dual-goal approach Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 705 - 713. [Abstract] [Full Text] [PDF]

				T. Berl Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2443 - 2447. [Full Text] [PDF]

				D. de Zeeuw and I. Raz Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes Diabetes Care, February 1, 2008; 31(Supplement_2): S190 - S193. [Full Text] [PDF]

				R. Kunz, C. Friedrich, M. Wolbers, and J. F.E. Mann Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease Ann Intern Med, January 1, 2008; 148(1): 30 - 48. [Abstract] [Full Text] [PDF]

				M. Burnier Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 208 - 211. [PDF]

				Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]

				F. F. Hou, D. Xie, X. Zhang, P. Y. Chen, W. R. Zhang, M. Liang, Z. J. Guo, and J. P. Jiang Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1889 - 1898. [Abstract] [Full Text] [PDF]

				P. Rossing, H.-H. Parving, and D. de Zeeuw Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction? Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2354 - 2357. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673